Zydus Pharmaceuticals Inc, USA (a 100% subsidiary of Cadila Healthcare Limited (Zydus Cadila), a
leading innovation-driven, global healthcare provider, has signed a license and supply agreement with
CHEMI SpA (“CHEMI”) of Italy, a subsidiary of Italfarmaco Group, to launch the generic equivalent
of Sanofi Aventis’s branded product Lovenox® (Enoxaparin Sodium Injection) in seven dosage
strengths in the United States (US).
Under the agreement, CHEMI will manufacture and supply the Enoxaparin Sodium Injection which
Zydus will commercialize in the US. CHEMI owns proprietary rights on a pharmaceutical product
composed of Enoxaparin Sodium (Preservative Free) single-use pre-filled syringes, which is an AP-
rated generic version of the branded product Lovenox®. CHEMI, utilizing their proprietary technology,
will produce the Enoxaparin Sodium injection within proprietary manufacturing facilities located in
Italy. CHEMI within ITF group is also vertically integrated on the Enoxaparin Sodium API
manufacturing which ensures quality and an uninterrupted supply of the critical care product.
Speaking on the development, Managing Director of Cadila Healthcare Limited, Dr. Sharvil Patel said,
“This partnership between Zydus and CHEMI is another step in our unwavering commitment to
improving the supply of critical care drugs, which are vital in delivering quality patient care. In addition,
this collaboration will bolster the Zydus injectable portfolio and demonstrates Zydus’ long-term
commitment to drive growth through investment in complex generic products. We’re proud to be the
first Indian company to launch a generic version of Enoxaparin in the United States and are excited
about this opportunity.”
Enoxaparin Sodium Injection, USP is used for prophylaxis of Deep Vein Thrombosis (DVT) in patients
undergoing abdominal, hip or knee replacement surgery, and also for the treatment of acute DVT.
Enoxaparin acts as blood thinner by producing an antithrombotic effect. Enoxaparin Injection had
annual sales of approximately $513 million in the United States, according to IQVIA data as of June
2021.